Press releases

29 May, 2020

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announced an increase of the number of shares and votes in Abliva of 83,720,875 as a result of a fully performed preferential rights issue, resolved by the Boa ...

20 May, 2020

Last day of trading with BTA in NeuroVive

The rights issue in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”) has today been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and paid subscribed sh ...

5 May, 2020

Regulatory

NeuroVive publishes outcome in rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company ...

22 April, 2020

Regulatory

NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a directed issue of shares totaling around MSEK 20 to Hadean Ventures (“Directed Issue”). Hade ...

19 February, 2020

Regulatory

NeuroVive proposes a rights issue of MSEK 74 and accelerates the clinical development of KL1333

Lund, Sweden, 19 February 2020, NeuroVive Pharmaceutical AB (Nasdaq Stockholm) today announced that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company") has reso ...

29 March, 2019

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 29 March 2019 - NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 22,594,467 as a result of ...

7 March, 2019

Regulatory

NeuroVive receives SEK 28.2 Million in a directed new share issue

Lund, Sweden, 7 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has successfully conducted a directed new issue of shares, which has rais ...

28 February, 2019

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 28 February 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 71,661,048 as a result ...

11 February, 2019

Regulatory

NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds

Lund, February 11, 2019 - NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the outcome of the preferential rights issue of shares ...

22 January, 2019

Regulatory

NeuroVive publishes prospectus in connection with preferential rights issue

Lund, Sweden, 22 January 2019 - NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the prospectus in connection with NeuroVive Pharmaceutical AB's (publ) ("N ...

28 December, 2018

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 28 December 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 126,235 as a result of ...

10 December, 2018

Regulatory

Outcome of the Exercise of Warrants in NeuroVive

Lund, Sweden, 10 December 2018 -NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announces the outcome of the exercise of warrants of serie ...